511 related articles for article (PubMed ID: 16121317)
1. Endothelin antagonism in pulmonary arterial hypertension.
Lee SH; Channick RN
Semin Respir Crit Care Med; 2005 Aug; 26(4):402-8. PubMed ID: 16121317
[TBL] [Abstract][Full Text] [Related]
2. An evidence-based approach to the management of pulmonary arterial hypertension.
Archer SL; Michelakis ED
Curr Opin Cardiol; 2006 Jul; 21(4):385-92. PubMed ID: 16755209
[TBL] [Abstract][Full Text] [Related]
3. Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension.
Beghetti M; Galiè N
J Am Coll Cardiol; 2009 Mar; 53(9):733-40. PubMed ID: 19245962
[TBL] [Abstract][Full Text] [Related]
4. [Endothelin receptor antagonists in the new European guidelines on pulmonary hypertension].
Montani D; Humbert M
Rev Mal Respir; 2010 Feb; 27(2):103-5. PubMed ID: 20206056
[No Abstract] [Full Text] [Related]
5. Endothelin receptor antagonists in pulmonary arterial hypertension.
Channick RN; Sitbon O; Barst RJ; Manes A; Rubin LJ
J Am Coll Cardiol; 2004 Jun; 43(12 Suppl S):62S-67S. PubMed ID: 15194180
[TBL] [Abstract][Full Text] [Related]
6. Management of pulmonary arterial hypertension with a focus on combination therapies.
Benza RL; Park MH; Keogh A; Girgis RE
J Heart Lung Transplant; 2007 May; 26(5):437-46. PubMed ID: 17449411
[TBL] [Abstract][Full Text] [Related]
7. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D
Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic treatment for pulmonary arterial hypertension.
Sastry BK
Curr Opin Cardiol; 2006 Nov; 21(6):561-8. PubMed ID: 17053404
[TBL] [Abstract][Full Text] [Related]
9. Advances in diagnosis and treatment in patients with pulmonary arterial hypertension.
Park MH
Catheter Cardiovasc Interv; 2008 Feb; 71(2):205-13. PubMed ID: 18327839
[TBL] [Abstract][Full Text] [Related]
10. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N
Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490
[TBL] [Abstract][Full Text] [Related]
11. Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension.
Steiner MK; Preston IR
Vasc Health Risk Manag; 2008; 4(5):943-52. PubMed ID: 19183742
[TBL] [Abstract][Full Text] [Related]
12. An evidence-based approach to the management of pulmonary arterial hypertension.
Coyne TC
Curr Opin Cardiol; 2006 Sep; 21(5):526; author reply 526-7. PubMed ID: 16900019
[No Abstract] [Full Text] [Related]
13. Endothelin receptor antagonists for pulmonary arterial hypertension.
Liu C; Chen J
Cochrane Database Syst Rev; 2006 Jul; (3):CD004434. PubMed ID: 16856046
[TBL] [Abstract][Full Text] [Related]
14. Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment.
Hall SM; Davie N; Klein N; Haworth SG
Eur Respir J; 2011 Oct; 38(4):851-60. PubMed ID: 21406517
[TBL] [Abstract][Full Text] [Related]
15. Sildenafil added to sitaxsentan in overcirculation-induced pulmonary arterial hypertension.
Rondelet B; Dewachter L; Kerbaul F; Dewachter C; Hubloue I; Fesler P; Franck S; Remmelink M; Brimioulle S; Naeije R
Am J Physiol Heart Circ Physiol; 2010 Oct; 299(4):H1118-23. PubMed ID: 20693396
[TBL] [Abstract][Full Text] [Related]
16. Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.
Langleben D
Clin Chest Med; 2007 Mar; 28(1):117-25, viii. PubMed ID: 17338931
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary arterial hypertension: the race for the most effective treatment.
McLaughin VV; Hoeper MM
Am J Respir Crit Care Med; 2005 Jun; 171(11):1199-201. PubMed ID: 15914567
[No Abstract] [Full Text] [Related]
18. Successful up-front combination therapy in a patient with idiopathic pulmonary hypertension and patent foramen ovale: an alternative to epoprostenol therapy?
Pitsiou GG; Chavouzis N; Nakou C; Boutou AK; Argyropoulou P; Stanopoulos I
J Heart Lung Transplant; 2009 Jun; 28(6):651-3. PubMed ID: 19481029
[TBL] [Abstract][Full Text] [Related]
19. Dual ET(A)/ET(B) vs. selective ET(A) endothelin receptor antagonism in patients with pulmonary hypertension.
Opitz CF; Ewert R
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():1-9. PubMed ID: 16919004
[TBL] [Abstract][Full Text] [Related]
20. Ironic case of hepatic dysfunction following the global withdrawal of sitaxentan.
Don GW; Joseph F; Celermajer DS; Corte TJ
Intern Med J; 2012 Dec; 42(12):1351-4. PubMed ID: 23253000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]